Volatile Organic Compounds
16
3
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT
BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED
Work Should Not Hurt You: Reduction of Hazardous Exposures in Small Businesses Through a Community Health Worker Intervention
Addressing Tetrachloroethylene Exposure in an Impacted Community
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors
Prognostic Value of Exhaled Isoprene Levels for Morbidity and Functional Outcome in Cardiosurgical Patients
VOC in Breath Samples for the Diagnosis of IPA
Tuberculosis Screening in Paraguayan Prisons
Effect of Surgical Smoke on Air Quality
Analysis of Volatile Organic Compounds in the Exhaled Air in Inflammatory Bowel Disease
Volatile Organic Compounds (VOCs) of Exhaled Breath in Patients With GI Bleeding
Cancer Diagnoses From Exhaled Breath With Na-nose
Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes
Prevention of CF Exacerbation in Childhood: PREVEC Study
Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study